Treating cancer using electromagnetic fields in combination with other treatment regimens
US8019414B2 · kind B2 · utility
Assignee
Inventor
Key dates
| Filing date | Apr 2, 2007 |
| Grant date | Sep 13, 2011 |
| Priority date | — |
| Expiry date | Apr 11, 2029 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61N1/326
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Chemotherapeutic treatment for certain cancers may be combined with low intensity, intermediate frequency alternating electric fields that are tuned to a particular type of target cell. When the tuned fields were combined with Paclitaxel, Doxorubicin or Cyclophosphamide, excellent results were obtained against human breast cancer cells (MDA-MB-231) and non-small cell lung (H1299) carcinomas in culture. More specifically, cell proliferation inhibition similar to that obtained by drug alone was reached by exposure to the combined treatment at drug concentrations between one and two orders of magnitude lower than for drug-only regimens of treatment.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.